Pipeline
Product Candidates
Leapfrog’s pipeline consists of multiple clinically tested small molecule compounds that have the potential to be blockbuster treatments for genetically defined cancers. As described in our recent AACR presentation, we expect to initiate a clinical trial of our lead program, LFB190, for the treatment of lung, bladder and other cancers with an EP300 loss of function mutation in 2025. EP300 mutations occur in approximately 6% of non-small cell lunger cancers, 15% of bladder cancers patients and between 5% and 10% of several other significant solid tumor cancers. Our second program, LFB188, is targeted against a genetic mutation that is responsible for over 100,000 cases of cancer per year in the US alone; it is anticipated to enter the clinic in 2026. We are also continuing our development efforts with respect to LFB101 and several other promising candidates identified by our Precision PGx Platform.
Pipeline Expansion
Leapfrog is continuing to screen compounds with its Precision PGx Platform and has discovered additional potential therapeutics for the treatment of cancers where there is a high unmet clinical need. These hits will be further validated in PDX and CDX models to confirm their effectiveness against cancers with the sensitizing genetic mutations identified by the platform. Leapfrog intends to advance these discoveries by either leveraging existing clinical data to restart development of these compounds in Phase 2 or by developing new chemical entities against the platform-identified targets.
Partnering
We work with pharmaceutical and biotechnology companies to retarget shelved product candidates for use in newly defined oncology indications. Depending on the product candidate and the interests of the partner, we can in-license or co-develop product candidates or explore spin-outs and other forms of partnership. We also seek to screen portfolios of pre-clinical candidates, R&D libraries, and shelved candidates to determine which compounds have the potential to be developed as targeted oncology therapeutics.
Please contact bd@leapfrog.bio for more information.